Layla Parast

Generating author description...

All published works

Action	Title	Year	Authors
+	A General Framework to Assess Complex Heterogeneity in the Strength of a Surrogate Marker	2025	Rebecca Kathryn Knowlton Lü Tian Layla Parast
+	SurrogateSeq: Group Sequential Testing of a Treatment Effect Using a Surrogate Marker	2025	Layla Parast Jay Bartroff
+ PDF Chat	Robust evaluation of longitudinal surrogate markers with censored data	2024	Denis Agniel Layla Parast
+ PDF Chat	Model-free Approach to Evaluate a Censored Intermediate Outcome as a Surrogate for Overall Survival	2024	Xuan Wang Tianxi Cai Lü Tian Layla Parast
+ PDF Chat	Semiparametric Joint Modeling to Estimate the Treatment Effect on a Longitudinal Surrogate with Application to Chronic Kidney Disease Trials	2024	Xuan Wang Jie Zhou Layla Parast Tom Greene
+	Group sequential testing of a treatment effect using a surrogate marker	2024	Layla Parast Jay Bartroff
+ PDF Chat	Group Sequential Testing of a Treatment Effect Using a Surrogate Marker	2024	Layla Parast Jay Bartroff
+ PDF Chat	Robust Evaluation of Longitudinal Surrogate Markers with Censored Data	2024	Denis Agniel Layla Parast
+	SurrogateBMA: Flexible Evaluation of Surrogate Markers with Bayesian Model Averaging	2024	Yunshan Duan Layla Parast
+ PDF Chat	A rank-based approach to evaluate a surrogate marker in a small sample setting	2024	Layla Parast Tianxi Cai Lü Tian
+	Statistical Methods to Evaluate Surrogate Markers	2023	Layla Parast Lü Tian Tianxi Cai Latha Palaniappan
+	Flexible evaluation of surrogate markers with Bayesian model averaging	2023	Yunshan Duan Layla Parast
+ PDF Chat	Can earlier biomarker measurements explain a treatment effect on diabetes incidence? A robust comparison of five surrogate markers	2023	Layla Parast Lü Tian Tianxi Cai Latha Palaniappan
+	Towards Optimal Use of Surrogate Markers to Improve Power	2023	Xuan Wang Layla Parast Lü Tian Tianxi Cai
+	Using a surrogate with heterogeneous utility to test for a treatment effect	2022	Layla Parast Tianxi Cai Lü Tian
+	hettest: Testing for a Treatment Effect Using a Heterogeneous Surrogate Marker	2022	Layla Parast
+	longsurr: Longitudinal Surrogate Marker Analysis	2022	Layla Parast Denis Agniel
+ PDF Chat	Doubly robust evaluation of high-dimensional surrogate markers	2022	Denis Agniel Boris P. Hejblum Rodolphe Thiébaut Layla Parast
+	Robust Approach to Combining Multiple Markers to Improve Surrogacy	2022	Xuan Wang Layla Parast Larry Han Lü Tian Tianxi Cai
+	Estimation of the proportion of treatment effect explained by a high‐dimensional surrogate	2022	Ruixuan Zhou Sihai Dave Zhao Layla Parast
+	Towards Optimal Use of Surrogate Markers to Improve Power	2022	Xuan Wang Layla Parast Lü Tian Tianxi Cai
+	Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect	2022	Layla Parast Tianxi Cai Lü Tian
+	Testing for Heterogeneity in the Utility of a Surrogate Marker	2021	Layla Parast Tianxi Cai Lü Tian
+	Quantifying the feasibility of shortening clinical trial duration using surrogate markers	2021	Xuan Wang Tianxi Cai Lü Tian Florence T. Bourgeois Layla Parast
+	Quantifying the Bias Due to Observed Individual Confounders in Causal Treatment Effect Estimates: A Tutorial for the Selection Bias Decomposition (SBdecomp) Package	2020	Layla Parast Beth Ann Griffin
+	Robust methods to correct for measurement error when evaluating a surrogate marker	2020	Layla Parast Tanya P. Garcia Ross L. Prentice Raymond J. Carroll
+	Evaluating multiple surrogate markers with censored data	2020	Layla Parast Tianxi Cai Lü Tian
+	Evaluation of longitudinal surrogate markers	2020	Denis Agniel Layla Parast
+	Quantifying the bias due to observed individual confounders in causal treatment effect estimates	2020	Layla Parast Beth Ann Griffin
+ PDF Chat	When is a Match Sufficient? A Score-based Balance Metric for the Synthetic Control Method	2020	Layla Parast Priscillia Hunt Beth Ann Griffin David Powell
+ PDF Chat	Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker	2019	Xuan Wang Layla Parast Lü Tian Tianxi Cai
+ PDF Chat	Using a Surrogate Marker for Early Testing of a Treatment Effect	2019	Layla Parast Tianxi Cai Lü Tian
+	Assessing the value of a censored surrogate outcome	2019	Layla Parast Lü Tian Tianxi Cai
+ PDF Chat	Evaluating surrogate marker information using censored data	2017	Layla Parast Tianxi Cai Lü Tian
+ PDF Chat	Optimizing variance-bias trade-off in the TWANG package for estimation of propensity scores	2016	Layla Parast Daniel F. McCaffrey Lane F. Burgette Fernando Hoces de la Guardia Daniela Golinelli Jeremy N. V. Miles Beth Ann Griffin
+ PDF Chat	Discussion of “A risk‐based measure of time‐varying prognostic discrimination for survival models,” by C. Jason Liang and Patrick J. Heagerty	2016	Layla Parast Carolyn M. Rutter
+	Nonparametric Estimation of the Proportion of Treatment Effect Explained by a Surrogate Marker using Censored Data	2016	Layla Parast Tianxi Cai Lü Tian
+	Landmark estimation of survival and treatment effects in observational studies	2016	Layla Parast Beth Ann Griffin
+	Evaluating Surrogate Marker Information using Censored Data	2016	Layla Parast Tianxi Cai Lü Tian
+ PDF Chat	Robust estimation of the proportion of treatment effect explained by surrogate marker information	2015	Layla Parast Mary Mcdermott Lü Tian
+	Landmark Prediction of Survival	2013	Layla Parast
+	Evaluating Incremental Values from New Predictors with Net Reclassification Improvement in Survival Analysis	2013	Yingye Zheng Layla Parast Tianxi Cai Marshall Brown
+ PDF Chat	Evaluating incremental values from new predictors with net reclassification improvement in survival analysis	2012	Yingye Zheng Layla Parast Tianxi Cai Marshall Brown
+ PDF Chat	Landmark Prediction of Long-Term Survival Incorporating Short-Term Event Time Information	2012	Layla Parast Su‐Chun Cheng Tianxi Cai
+ PDF Chat	Incorporating short‐term outcome information to predict long‐term survival with discrete markers	2011	Layla Parast Su‐Chun Cheng Tianxi Cai
+ PDF Chat	Meta-analysis for rare events	2010	Tianxi Cai Layla Parast Louise Ryan

Common Coauthors

Coauthor	Papers Together
Tianxi Cai	21
Lü Tian	20
Xuan Wang	7
Beth Ann Griffin	5
Denis Agniel	5
Jay Bartroff	3
Yunshan Duan	2
Yingye Zheng	2
Su‐Chun Cheng	2
Latha Palaniappan	2
Marshall Brown	2
Tianxi Cai	2
Sihai Dave Zhao	1
Carolyn M. Rutter	1
Jeremy N. V. Miles	1
Mary Mcdermott	1
Louise Ryan	1
Rebecca Kathryn Knowlton	1
Fernando Hoces de la Guardia	1
Tom Greene	1
Tanya P. Garcia	1
Raymond J. Carroll	1
Rodolphe Thiébaut	1
David Powell	1
Priscillia Hunt	1
Daniel F. McCaffrey	1
Daniela Golinelli	1
Larry Han	1
Ruixuan Zhou	1
Lane F. Burgette	1
Jie Zhou	1
Ross L. Prentice	1
Boris P. Hejblum	1
Florence T. Bourgeois	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Statistical validation of intermediate endpoints for chronic diseases	1992	Laurence S. Freedman Barry I. Graubard Arthur Schatzkin	22
+ PDF Chat	A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker	2002	Wang Yue Jeremy M. G. Taylor	21
+ PDF Chat	Surrogate Measures and Consistent Surrogates	2013	Tyler J. VanderWeele	20
+ PDF Chat	Robust estimation of the proportion of treatment effect explained by surrogate marker information	2015	Layla Parast Mary Mcdermott Lü Tian	18
+	Surrogate endpoints in clinical trials: Definition and operational criteria	1989	Ross L. Prentice	18
+ PDF Chat	Evaluating surrogate marker information using censored data	2017	Layla Parast Tianxi Cai Lü Tian	17
+	ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER	1997	D. Y. Lin Thomas R. Fleming Victor De Gruttola	16
+ PDF Chat	Evaluating Candidate Principal Surrogate Endpoints	2008	Peter B. Gilbert Michael G. Hudgens	15
+	Multivariate Density Estimation	1992	David W. Scott	14
+ PDF Chat	Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal	2013	A. S. C. Conlon Jeremy M. G. Taylor Michael R. Elliott	13
+ PDF Chat	Comparing Biomarkers as Principal Surrogate Endpoints	2011	Ying Huang Peter B. Gilbert	12
+ PDF Chat	Surrogacy marker paradox measures in meta-analytic settings	2014	Michael R. Elliott A. S. C. Conlon Y. Li Niko Kaciroti Jeremy M. G. Taylor	12
+	Criteria for the Validation of Surrogate Endpoints in Randomized Experiments	1998	Marc Buyse Geert Molenberghs	11
+ PDF Chat	Estimation of the optimal surrogate based on a randomized trial	2018	Brenda Price Peter B. Gilbert Mark J. van der Laan	11
+ PDF Chat	Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker	2019	Xuan Wang Layla Parast Lü Tian Tianxi Cai	10
+ PDF Chat	Counterfactual Links to the Proportion of Treatment Effect Explained by a Surrogate Marker	2005	Jeremy M. G. Taylor Yue Wang Rodolphe Thiébaut	9
+ PDF Chat	Principal Stratification in Causal Inference	2002	Constantine Frangakis Donald B. Rubin	9
+ PDF Chat	Using a Surrogate Marker for Early Testing of a Treatment Effect	2019	Layla Parast Tianxi Cai Lü Tian	8
+ PDF Chat	Model evaluation based on the sampling distribution of estimated absolute prediction error	2007	Lü Tian Tommaso Cai Els Goetghebeur L. J. Wei	7
+ PDF Chat	Semiparametric Box–Cox power transformation models for censored survival observations	2005	Tianxi Cai Lü Tian L. J. Wei	7
+	Related Causal Frameworks for Surrogate Outcomes	2008	Marshall M. Joffe Tom Greene	6
+ PDF Chat	Calibrating parametric subject-specific risk estimation	2010	Tianxi Cai Lü Tian Hajime Uno Scott D. Solomon L. J. Wei	6
+ PDF Chat	Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints	2014	Erin E. Gabriel Michael C. Sachs Peter B. Gilbert	5
+ PDF Chat	The central role of the propensity score in observational studies for causal effects	1983	Paul R. Rosenbaum Donald B. Rubin	5
+ PDF Chat	Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data	2007	Debashis Ghosh	5
+	Evaluating multiple surrogate markers with censored data	2020	Layla Parast Tianxi Cai Lü Tian	5
+	Testing for Heterogeneity in the Utility of a Surrogate Marker	2021	Layla Parast Tianxi Cai Lü Tian	5
+ PDF Chat	On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial	2012	Lü Tian Tianxi Cai Lihui Zhao L. J. Wei	5
+ PDF Chat	Surrogate Endpoints in Clinical Trials	2023	Michael R. Elliott	5
+	Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers	1992	James M. Robins Andrea Rotnitzky	5
+ PDF Chat	On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm	2008	Debashis Ghosh	4
+ PDF Chat	Statistical challenges in the evaluation of surrogate endpoints in randomized trials	2002	Geert Molenberghs Marc Buyse Helena Geys Didier Renard Tomasz Burzykowski Ariel Alonso	4
+ PDF Chat	The validation of surrogate endpoints in meta-analyses of randomized experiments	2000	Marc Buyse Geert Molenberghs Tomasz Burzykowski Didier Renard Helena Geys	4
+	Evaluation of longitudinal surrogate markers	2020	Denis Agniel Layla Parast	4
+	Some Problems in Interval Estimation	1954	E. C. Fieller	4
+	Non-parametric regression with censored survival time data	1987	Dorota M. Dabrowska	4
+ PDF Chat	Improving propensity score weighting using machine learning	2009	Brian K. Lee Justin Lessler Elizabeth A. Stuart	4
+ PDF Chat	Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates	2008	Mélanie Prague Rui Wang Stephens Alisa Tchetgen Eric Victor De Gruttola	4
+	Efficiency improvement in a class of survival models through model-free covariate incorporation	2011	Tanya P. Garcia Yanyuan Ma Guosheng Yin	4
+	Evaluating Prediction Rules for<i>t</i>-Year Survivors With Censored Regression Models	2007	Hajime Uno Tianxi Cai Lü Tian L. J. Wei	4
+	Evaluating the role of CD4‐lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials	1993	D. Y. Lin Margaret A. Fischl David Schoenfeld	4
+	The Surrogate Index: Combining Short-Term Proxies to Estimate Long-Term Treatment Effects More Rapidly and Precisely	2019	Susan Athey Raj Chetty Guido W. Imbens Hyunseung Kang	4
+ PDF Chat	Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research.	2010	Valerie S. Harder Elizabeth A. Stuart James C. Anthony	3
+	Empirical Processes: Theory and Applications	1990	David Pollard	3
+ PDF Chat	Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction	2007	Nancy R. Cook	3
+	Propensity Score Estimation With Boosted Regression for Evaluating Causal Effects in Observational Studies.	2004	Daniel F. McCaffrey Greg Ridgeway Andrew R. Morral	3
+	TOWARD A CURSE OF DIMENSIONALITY APPROPRIATE (CODA) ASYMPTOTIC THEORY FOR SEMI‐PARAMETRIC MODELS	1997	James M. Robins Ya’acov Ritov	3
+ PDF Chat	On Inference in Parametric Survival Data Models	1992	Nils Lid Hjort	3
+	The Evaluation of Multiple Surrogate Endpoints	2001	Jane Xu Scott L. Zeger	3
+ PDF Chat	Covariate Balancing Propensity Score	2013	Kosuke Imai Marc Ratkovic	3